Steven Cohen Viking Therapeutics, Inc. Transaction History

Point72 Asset Management, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$17.4 - $94.5 $2.33 Million - $12.7 Million	133,990 New	133,990 $11 Million
Q2 2023 Aug 14, 2023	SELL	$14.84 - $24.79 $11.7 Million - $19.6 Million	-789,378 Reduced 72.2%	303,957 $4.93 Million
Q1 2023 May 15, 2023	SELL	$8.08 - $17.33 $99,101 - $212,552	-12,265 Reduced 1.11%	1,093,335 $18.2 Million
Q4 2022 Feb 14, 2023	BUY	$2.72 - $9.4 $3.01 Million - $10.4 Million	1,105,600 New	1,105,600 $10.4 Million

473

66.2M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.03B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.